comparemela.com

Latest Breaking News On - Martin olin - Page 8 : comparemela.com

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet.

United statesUnited kingdomPrnewswire bergenbioJan lillebyNigel mccrackenMartin olinGraham morrellAmerican association for cancer researchOslo stock exchangeNon small cell lung cancerTherapeutic targetAmerican associationCancer researchAnnual meetingChief scientific officerScientific presentations

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet.

United kingdomUnited statesJan lillebyGraham morrellTony mokEnriqueta felipMartin olinSolange petersJohn heymachInvestor relations international mediaHebron university hospitalMd anderson cancer centerChinese university of hong kongDepartment of oncology at lausanne universityDepartment of clinical oncologyClinical development

BerGenBio ASA: BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

BERGEN, Norway, Feb. 16, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

United kingdomUnited statesDennis riedlJan lillebyMartin olinJohn heymachTony mokGraham morrellEnriqueta felipPrnewswire bergenbioSolange petersInvestor relations international mediaHebron university hospitalMd anderson cancer centerChinese university of hong kongDepartment of oncology at lausanne university

BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patie

- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February.

United statesUnited kingdomCity ofMartin olinJames spicerPrnewswire bergenbioInvestor relations international mediaCo incOslo stock exchangeNon small cell lung cancerChief executive officerExperimental cancer medicineCollege londonPrincipal investigatorInternational media

BerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET - BERGEN, Norway, Feb. 15, 2023 /PRNewswire/ BerGenBio

United statesUnited kingdomCity ofDennis riedlGraham morrellJan lillebyMartin olinJames spicerPrnewswire bergenbioInvestor relations international mediaCo incOslo stock exchangeNon small cell lung cancerChief executive officerExperimental cancer medicineCollege london

vimarsana © 2020. All Rights Reserved.